Prognostic role of heart-type fatty acid binding protein in pulmonary embolism: a meta-analysis.

Abstract Introduction Pulmonary embolism (PE) has a high morbidity and mortality. Hence it is important to recognize factors associated with higher risk of adverse outcomes in hemodynamically stable patients. Heart-type fatty acid binding protein (H-FABP) is a novel marker evaluated in recent years for prognosis in acute PE. Our aim was to evaluate the available evidence on the accuracy of H-FABP for predicting the prognosis of adverse clinical outcomes (defined as the occurrence of any of the following: death, cardiopulmonary resuscitation, endotracheal intubation, use of vasopressors, thrombolysis, surgical embolectomy, or admission to the intensive care unit) or mortality in patients with acute PE. Methods Unrestricted searches of PubMed, the Cochrane Library, Web of Science and Science Direct were performed using the terms of “H-FABP” or "heart-type fatty acid binding protein" and ("pulmonary embolism" or "pulmonary thromboembolism"). A random-effect model was used to pool study results; χ 2 and I 2 testing was used to test for heterogeneity. Data of six studies were included in this analysis. Results 34 of 119(28.57%; 95%CI, 20.42%—36.72%) patients with elevated H-FABP levels had adverse events during follow-up compared with 24 of 475 (5.05%; 95%CI, 3.08%—7.02%) patients with normal levels. High H-FABP levels were associated with a high risk of occurrence of adverse clinical outcome (pooled OR, 10.81; 95%CI, 3.92—29.83). Conclusion The results of this meta-analysis indicate that H-FABP is a good predictor for adverse outcomes in patients with acute PE.